Looking for Adalimumab found 35 matches
|
Open monograph to display formulary status |
BNF Category |
|
Adalimumab
|
Gastro-intestinal system - Cytokine inhibitors - 01.05.03
|
|
Adalimumab
|
Musculoskeletal and joint diseases - Drugs affecting the immune response - 10.01.03
|
|
Adalimumab
|
Skin - Drugs affecting the immune response - 13.05.03
|
|
Links Link to Drug Section Link to document |
NICE TA134: Ankylosing spondylitis - adalimumab, etanercept and infliximab (10.01.03)
|
NICE TA146 Adalimumab for the treatment of adults with psoriasis (10.01.03)
|
NICE TA146 Adalimumab for the treatment of psoriasis (13.05.03)
|
NICE TA187 Infliximab and adalimumab for the treatment of Crohn’s disease (01.05.03)
|
NICE TA187 Infliximab and adalimumab for the treatment of Crohn’s disease (01.05.03)
|
NICE TA187: Infliximab (review) and adalimumab for the treatment of Crohn’s disease (01.05.03)
|
NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
|
NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
|
NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
|
NICE TA195 Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
|
NICE TA195: Rheumatoid arthritis - Adalimumab, etanercept, infliximab, rituximab and abatacept (10.01)
|
NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (13.05.03)
|
NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
|
NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
|
NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (13.05.03)
|
NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (13.05.03)
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (10.01.03)
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (10.01.03)
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (10.01.03)
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
|
NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
NICE TA373 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
|
|
|